Advancing drug innovation for neglected diseases-criteria for lead progression.
The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts.
Nwaka
Solomon
S
Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.
Ramirez
Bernadette
B
Brun
Reto
R
Maes
Louis
L
Douglas
Frank
F
Ridley
Robert
R
Nat Rev Drug Discov. 2004 Aug;3(8):673-83
15286734
Science. 2005 Jul 15;309(5733):436-42
16020728
Nat Rev Drug Discov. 2007 Jan;6(1):29-40
17159923
Lancet. 2002 Jun 22;359(9324):2188-94
12090998
Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S4-8
16904717
Nature. 2005 Mar 10;434(7030):214-7
15759000
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15
15331814
Nat Rev Drug Discov. 2002 Jan;1(1):45-54
12119609
Expert Opin Drug Discov. 2007 Oct;2(s1):S3-7
23489030
Nat Rev Drug Discov. 2008 Nov;7(11):900-7
18927591
Nat Rev Drug Discov. 2003 May;2(5):369-78
12750740
PLoS Med. 2007 Nov 6;4(11):e293
17988169
N Engl J Med. 2008 Dec 11;359(24):2619-20
19064625
Drug Discov Today. 2005 Jan 1;10(1):17-22
15676295
Science. 2005 Jul 15;309(5733):401-4
16020723
PLoS Med. 2005 Sep;2(9):e302
16138789
Science. 2005 Jul 15;309(5733):409-15
16020725
Nat Rev Drug Discov. 2003 Nov;2(11):919-28
14668812
Adv Parasitol. 2006;61:349-94
16735169
Science. 2007 Sep 21;317(5845):1756-60
17885136
Parasitology. 2007;134(Pt 8):1073-6
17608966
J Biol Chem. 2005 Jun 10;280(23):21847-53
15795226
Postgrad Med J. 2006 Dec;82(974):788-98
17148699
Expert Opin Drug Discov. 2007 Oct;2(s1):S53-61
23489033
Nat Rev Drug Discov. 2006 Nov;5(11):941-55
17080030
Nat Rev Drug Discov. 2005 Sep;4(9):727-40
16138106
Nature. 2002 Oct 3;419(6906):498-511
12368864
Expert Opin Drug Discov. 2007 Oct;2(s1):S63-73
23489034
Expert Opin Drug Discov. 2007 Oct;2(s1):S41-52
23489032
Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):19-51
18221162
Exp Parasitol. 2007 Nov;117(3):225-8
17643433
Expert Opin Drug Discov. 2007 Oct;2(s1):S99-S103
23489039
J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49
11274893
Science. 2005 Jul 15;309(5733):416-22
16020726
Health Aff (Millwood). 2006 Mar-Apr;25(2):420-8
16522582
Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S21-5
16730039
J Health Econ. 2003 Mar;22(2):151-85
12606142
Nat Rev Drug Discov. 2002 Nov;1(11):882-94
12415248
Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S20-9
16085175
Bioorg Med Chem Lett. 2007 Mar 1;17(5):1422-7
17194585
Nature. 2004 Aug 19;430(7002):900-4
15318224
PLoS Med. 2005 Aug;2(8):e210
16120007
Nature. 2007 Sep 13;449(7159):166-9
17851512
Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S9-14
16087204
J Clin Invest. 2008 Apr;118(4):1266-76
18382739
J Enzyme Inhib Med Chem. 2008 Oct;23(5):708-18
18671165
Ernst Schering Res Found Workshop. 2003;(42):11-7
12664532